S-1: Kaya Holdings Files for Resale of 25 Million Shares Amidst Psychedelic and Cannabis Focus

Kaya Holdings, Inc. has filed a registration statement for the resale of up to 25 million shares of its common stock by selling stockholders, as the company focuses on its wellness and mental health operations.

Summary

• Kaya Holdings, Inc. has filed a registration statement for the resale of up to 25 million shares of its common stock by selling stockholders.
• The shares being sold have been issued or are issuable upon conversion of convertible promissory notes acquired by the selling stockholders.
• Kaya Holdings is a holding company focusing on wellness and mental health through operations in psychedelic treatment clinics, medical and recreational cannabis, and CBD products.
• The company operates The Sacred Mushroom Psychedelic Treatment Center in Portland, Oregon, as part of its Fifth Dimension Therapeutics subsidiary.
• Kaya Holdings has approximately ten years of operational experience in the legal cannabis industry, including retail, cultivation, and manufacturing.
• The company also has one retail cannabis license in Oregon and two medical marijuana production and processing licenses in Greece.
• The company is exploring opportunities in the psychedelic treatment space, with Oregon being the first state to legalize and license the supervised use of psilocybin.
• The company received its license for its psilocybin treatment facility from the OHA in April 2024 and began providing treatments in September 2024.
• The selling stockholders will bear all commissions and discounts, while the company will bear all costs, expenses, and fees in connection with the registration of the shares.
• The company will not receive any proceeds from the sale of common stock offered by the selling stockholders.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is pioneering in the psilocybin treatment space and has a history in cannabis, it faces significant financial challenges, including losses, limited cash, and substantial doubt about its ability to continue as a going concern. The company's reliance on future financing and the risks associated with its business model contribute to a negative sentiment.

Positives

• Kaya Holdings is a first mover in the legal psilocybin treatment space in Oregon.
• The company has a decade of experience in the cannabis industry, which may provide a competitive advantage.
• The company has a vertically integrated cannabis operation, including retail, cultivation, and manufacturing.
• The company has a flagship psychedelic treatment facility in Portland, Oregon, which it plans to replicate elsewhere.
• The company has a strong understanding of Oregon regulations, having previously navigated the OHA licensing process for cannabis.

Negatives

• The company has a history of losses and has limited cash on hand.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a relatively short operating history in its current psychedelic treatment business.
• The company is dependent on key individuals, and the loss of one could have an adverse effect.
• The company faces significant competition in both the cannabis and psilocybin industries.
• The company's common stock is classified as a penny stock, which may limit trading activity.

Risks

• The company has incurred significant losses and has limited cash on hand, raising substantial doubt about its ability to continue as a going concern.
• The company has a limited operating history in its current business, particularly in the psilocybin treatment sector.
• The company will require additional financing to become commercially viable, and there is no assurance that it will be available.
• The company is dependent on key individuals, and the loss of one could have an adverse effect.
• The company must effectively manage expanding operations, which could strain managerial, operational, and financial resources.
• Marijuana and psilocybin remain illegal under federal law, which could adversely affect the company's operations.
• The market acceptance of marijuana and psilocybin may not be as rapid as the company expects.
• The company's business could be affected by changes in governmental regulation.
• The company will likely face significant competition in both the cannabis and psilocybin industries.
• The trading market for the company's common stock is extremely limited and sporadic.
• The company's common stock is classified as a penny stock, which may limit a stockholder's ability to buy and sell shares.

Future Outlook

The company plans to utilize The Sacred Mushroom treatment facility as a flagship model to replicate elsewhere in Oregon and in other jurisdictions which may subsequently legalize such psychedelic treatments. Management believes that proceeds expected to be received from financing transactions that it is seeking to enter into, combined with existing and anticipated revenues, will alleviate the Companys financial difficulties to a significant extent and will allow the Company to meet its anticipated working capital needs for a period of between twelve and eighteen months from the date of this report.

Management Comments

• Management believes that it will be able to successfully execute its business plan, which includes third party financing and the raising of capital to meet the Companys future liquidity needs.
• Management believes that proceeds expected to be received from financing transactions that it is seeking to enter into, combined with existing and anticipated revenues, will alleviate the Companys financial difficulties to a significant extent and will allow the Company to meet its anticipated working capital needs for a period of between twelve and eighteen months from the date of this report.

Industry Context

The company is operating in the emerging industries of legal cannabis and psychedelic treatments, which are subject to evolving regulations and market acceptance. The company's move into psilocybin treatments is in line with a growing trend of exploring psychedelic medicines for mental health disorders. The company's experience in the cannabis industry may provide a competitive advantage in the psilocybin market.

Comparison to Industry Standards

• The company's psilocybin treatment center is one of the first of its kind in the United States, making direct comparisons difficult.
• Companies like Compass Pathways, ATAI Life Sciences, and Cybin are developing synthetic versions of psilocybin, while Kaya Holdings is focused on providing treatment services.
• The company's pricing for psilocybin treatments is at or near the lower range of the market, which may give it a competitive advantage.
• The company's facility is designed to provide a safe and comfortable environment for psilocybin treatments, which is a key factor in the success of such treatments.
• The company's cannabis operations are similar to other vertically integrated cannabis companies, but the company has reduced its US retail operations and expanded into overseas opportunities.

Legal Proceedings

• From time to time, the company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business.

Related Party Transactions

• The company has a consulting agreement with Tudog International Consulting, Inc., which provides CEO services through Craig Frank.
• The company has consulting agreements with Tudog International Consulting (Tudog) of which firm Mr. Frank is Chairman and a Principal, for the services of Mr. Frank as CEO and acting CFO.
• The company has consulting agreements with BMN Consultants, Inc. which provides business development and financial consulting services to the Company through William David Jones, a non-officer Consultant to the Company.

Stakeholder Impact

• Shareholders face a high degree of risk due to the company's financial condition and the speculative nature of its business.
• Employees may be affected by the company's financial instability and potential changes in operations.
• Customers may benefit from the company's psilocybin treatment services, but the availability and quality of these services may be affected by the company's financial condition.
• Suppliers and creditors may be at risk due to the company's financial instability.

Next Steps

• The company plans to replicate The Sacred Mushroom treatment facility elsewhere in Oregon and other jurisdictions.
• The company expects to enroll additional potential candidates in the psilocybin facilitator program.
• The company is seeking additional financing to support its operations and expansion.
• The company is evaluating redeploying its remaining dispensary license to serve as a delivery hub.

Key Dates

Keywords

psychedelic treatment, psilocybin, cannabis, marijuana, mental health, wellness, Oregon, OTCQB, convertible notes, penny stock